newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Third Quarter 2026 Financial Results and Business Update

  • Enrollment in the SUPRAME Phase 3 trial for anzu-cel is on track to complete required randomizations by year-end to support final analysis for the primary progression-free survival endpoint.
  • Topline data from the SUPRAME trial is expected in the first half of 2027, followed by a Biologics License Application (BLA) submission in 2027.
  • Updated Phase 1 data for IMA203CD8 presented at ESMO Congress 2026 showed a 55% confirmed objective response rate (cORR) 8.4 months median duration of response (mDOR) in patients with advanced gynecologic cancers.
  • Phase 1b data for the IMA402 PRAME bispecific presented at ESMO Congress 2026 demonstrated a 32% cORR, 12.5 months mDOR, 91% one-year overall survival rate, 1-year OS in patients with PRAME-high advanced melanoma.
  • Cash 1 cash equivalents 1 other financial assets totaled $536.3 million (€472.3 million) as of September 30, 2026, with cash projected to last through Q4 2028.
  • Jason Braun was appointed Chief Commercial Officer on September 28, 2026, to lead commercial infrastructure build-out for the anticipated anzu-cel launch.
  • Immatics operates a fully functional 100,000-square-foot R 1 cell therapy manufacturing facility in the Houston metropolitan area.
  • Total revenue for the third quarter of 2026 was $7.8 million (€6.9 million), driven by higher milestones 1 activity in collaboration programs.
  • Research 1 development expenses for the third quarter of 2026 were $79.8 million (€70.3 million), an increase attributed to advancing the SUPRAME trial.
  • Net loss for the third quarter of 2026 was $86.3 million (€76.0 million), primarily due to higher costs associated with the SUPRAME trial.
Company
Immatics N.V.
Keywords
Nasdaq:IMTX, Immatics N.V., Immatics N.V., IMTX, Cell Therapy, Immunooncology, Immunotherapy, TCR-Therapeutics, Quarterly report